Table 2.
Clinical characteristics of patients with irinotecan-based treatment in this study
| Characteristics | No. of patients (n=81) |
Frequency (%) |
|---|---|---|
| Mean age, years (range) | 58 (28–79) | |
| Gender | ||
| Male | 67 | 82.72 |
| Female | 14 | 17.28 |
| ECOG performance status | ||
| 0 | 47 | 58.02 |
| 1 | 31 | 38.27 |
| 2 | 2 | 2.47 |
| 3 | 1 | 1.23 |
| Type of tumor | ||
| Lung cancer | 45 | 55.56 |
| Colorectal cancer | 27 | 33.33 |
| Esophageal cancer | 9 | 11.11 |
| Habit of smoking and drinking | ||
| Smoking | 20 | 24.69 |
| Drinking | 5 | 6.17 |
| Smoking and drinking | 31 | 38.27 |
| None | 25 | 34.57 |
| Line of treatment | ||
| First line | 30 | 37.04 |
| Second line | 47 | 58.02 |
| Third line | 4 | 4.94 |
| Cycle of treatment | ||
| Second cycle | 34 | 41.98 |
| Third cycle | 24 | 29.63 |
| ≥ fourth cycle | 23 | 28.40 |
Abbreviation: ECOG, Eastern Cooperative Oncology Group.